Here is another interesting quote from the Wall St Journal article on Biogen.  I wonder what this means for RVX?

"Former FDA Commissioner Scott Gottlieb has advocated alternative trial designs that can be adapted based on early clinical data showing which patients are most likely to benefit from treatments. This has generated resistance from some in the medical community, but Biogen’s trials show how tailoring trials can illuminate positive effects."